CIK 0001082038
DRRX DURECT CORP
Insider trading from SEC Form 4. Last filing Sep 16, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Signals
Open-market buys and sells at DURECT CORP, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 7Weak | R Scott Asen owner buy | $11k 5,917 shares | +0% | - | |
| 29Weak | R Scott Asen owner buy | $387k 204,220 shares | +23% | - |
Transactions
The last 79 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -103,077 | - | - | 0 | Sep 16, 2025 |
| Sep 11, 2025 | Gail J Maderis director | UTender of shares Common Stock | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Norman Sussman Chief Medical Officer | DDisposition to issuer Common Stock | -46,425 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail M Farfel director | UTender of shares Common Stock | -15,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Peter S Garcia director | UTender of shares Common Stock | -12,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Timothy M. Papp Chief Financial Officer | UTender of shares Common Stock | -385,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Mohammad Azab director | UTender of shares Common Stock | -6,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Judith J. Robertson director | UTender of shares Common Stock | -41,113 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | UTender of shares Common Stock | -448,376 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Mohammad Azab director | DDisposition to issuer Stock Option (right to buy)derivative | -7,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Norman Sussman Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Judith J. Robertson director | DDisposition to issuer Stock Option (right to buy)derivative | -7,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | UTender of shares Common Stockindirect: by Brown 2006 Trust | -8,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail M Farfel director | DDisposition to issuer Stock Option (right to buy)derivative | -7,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail J Maderis director | UTender of shares Common Stockindirect: By Gail J. Maderis Revocable Trust dtd 04-08- 2013 Gail Maderis TTEE | -20,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Peter S Garcia director | DDisposition to issuer Stock Option (right to buy)derivative | -7,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Timothy M. Papp Chief Financial Officer | DDisposition to issuer Common Stock | -46,659 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Timothy M. Papp Chief Financial Officer | DDisposition to issuer Stock Option (right to buy)derivative | -60,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Norman Sussman Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -10,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail M Farfel director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Mohammad Azab director | DDisposition to issuer Stock Option (right to buy)derivative | -2,750 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Peter S Garcia director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Common Stock | -96,959 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail J Maderis director | DDisposition to issuer Stock Option (right to buy)derivative | -7,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Judith J. Robertson director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Timothy M. Papp Chief Financial Officer | DDisposition to issuer Stock Option (right to buy)derivative | -12,377 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Norman Sussman Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -39,837 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Mohammad Azab director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Peter S Garcia director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail J Maderis director | DDisposition to issuer Stock Option (right to buy)derivative | -2,750 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail M Farfel director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Judith J. Robertson director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -36,720 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Judith J. Robertson director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Norman Sussman Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -69,557 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail J Maderis director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail M Farfel director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Timothy M. Papp Chief Financial Officer | DDisposition to issuer Stock Option (right to buy)derivative | -60,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Mohammad Azab director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -4,807 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail M Farfel director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Norman Sussman Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -104,000 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Judith J. Robertson director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Mohammad Azab director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -37,067 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | Gail J Maderis director | DDisposition to issuer Stock Option (right to buy)derivative | -5,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -4,717 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -43,821 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -37,175 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -22,500 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -20,900 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -95,610 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -250,665 | - | - | 0 | Sep 12, 2025 |
| Sep 11, 2025 | James E Brown President & CEO | DDisposition to issuer Stock Option (right to buy)derivative | -103,077 | - | - | 0 | Sep 12, 2025 |
| Sep 9, 2025 | Peter S Garcia director | MOption exercise Common Stock | +5,500 | $1.22 | $6,710 | 12,500 | Sep 11, 2025 |
| Sep 10, 2025 | Judith J. Robertson director | MOption exercise Common Stock | +5,500 | $1.22 | $6,710 | 41,113 | Sep 11, 2025 |
| Sep 10, 2025 | Gail M Farfel director | MOption exercise Common Stock | +5,500 | $1.22 | $6,710 | 15,500 | Sep 11, 2025 |
| Sep 9, 2025 | Gail J Maderis director | MOption exercise Common Stock | +5,500 | $1.22 | $6,710 | 5,500 | Sep 11, 2025 |
| Sep 9, 2025 | James E Brown President & CEO | MOption exercise Common Stock | +131,923 | $1.30 | $171k | 415,335 | Sep 11, 2025 |
| Sep 10, 2025 | Judith J. Robertson director | MOption exercise Stock Option (right to buy)derivative | -5,500 | $0.00 | $0 | 0 | Sep 11, 2025 |
| Sep 9, 2025 | Peter S Garcia director | MOption exercise Stock Option (right to buy)derivative | -5,500 | $0.00 | $0 | 0 | Sep 11, 2025 |
| Sep 10, 2025 | Gail M Farfel director | MOption exercise Stock Option (right to buy)derivative | -5,500 | $0.00 | $0 | 0 | Sep 11, 2025 |
| Sep 10, 2025 | James E Brown President & CEO | MOption exercise Common Stock | +130,000 | $1.30 | $169k | 545,335 | Sep 11, 2025 |
| Sep 9, 2025 | Gail J Maderis director | MOption exercise Stock Option (right to buy)derivative | -5,500 | $0.00 | $0 | 0 | Sep 11, 2025 |
| Sep 9, 2025 | James E Brown President & CEO | MOption exercise Stock Option (right to buy)derivative | -131,923 | $0.00 | $0 | 233,077 | Sep 11, 2025 |
| Sep 10, 2025 | James E Brown President & CEO | MOption exercise Stock Option (right to buy)derivative | -130,000 | $0.00 | $0 | 103,077 | Sep 11, 2025 |
| Sep 8, 2025 | James E Brown President & CEO | MOption exercise Common Stock | +10,000 | $1.30 | $13k | 283,412 | Sep 10, 2025 |
| Sep 8, 2025 | James E Brown President & CEO | MOption exercise Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 365,000 | Sep 10, 2025 |
| Sep 8, 2025 | Timothy M. Papp Chief Financial Officer | MOption exercise Common Stock | +110,000 | $1.30 | $143k | 431,659 | Sep 9, 2025 |
| Sep 8, 2025 | Timothy M. Papp Chief Financial Officer | MOption exercise Stock Option (right to buy)derivative | -110,000 | $0.00 | $0 | 0 | Sep 9, 2025 |
| Aug 22, 2025 | R Scott Asen owner | POpen-market purchase Common Stock | +5,917 | $1.92 | $11k | 2,672,529 | Aug 26, 2025 |
| Aug 20, 2025 | R Scott Asen owner | POpen-market purchase Common Stockindirect: See Footnote | +87,608 | $1.89 | $165k | 970,000 | Aug 22, 2025 |
| Aug 21, 2025 | R Scott Asen owner | POpen-market purchase Common Stock | +116,612 | $1.90 | $221k | 2,666,612 | Aug 22, 2025 |
| Jul 11, 2025 | James E Brown President & CEO | AGrant or award Common Stock | +96,959 | $0.00 | $0 | 273,412 | Jul 15, 2025 |
| Jul 11, 2025 | Timothy M. Papp Chief Financial Officer | AGrant or award Common Stock | +46,659 | $0.00 | $0 | 321,659 | Jul 15, 2025 |
| Jul 11, 2025 | Norman Sussman Chief Medical Officer | AGrant or award Common Stock | +46,425 | $0.00 | $0 | 46,425 | Jul 15, 2025 |
| Oct 14, 2024 | James E Brown President & CEO | AGrant or award Stock Option (right to buy)derivative | +375,000 | $0.00 | $0 | 375,000 | Oct 16, 2024 |
| Oct 14, 2024 | Timothy M. Papp Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +110,000 | $0.00 | $0 | 110,000 | Oct 16, 2024 |
| Oct 14, 2024 | Norman Sussman Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +104,000 | $0.00 | $0 | 104,000 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- R Scott Asenowner
- Mohammad Azabdirector
- James E BrownPresident & CEO
- Gail M Farfeldirector
- Peter S Garciadirector
- Gail J Maderisdirector
- Timothy M. PappChief Financial Officer
- Judith J. Robertsondirector
- Norman SussmanChief Medical Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.